3693-06-9

Basic information

• Product Name: 2,3,4,5-tetrahydrobenzo[b][1,4]oxazepine
• Synonyms: 2,3,4,5-tetrahydrobenzo[b][1,4]oxazepine;1,3,4,5-TETRAHYDRO-5-OXA-BENZO[B]AZEPINE;1,2,3,5-Tetrahydrobenzo[e][1,4]oxazepine
• CAS NO: 3693-06-9
• Molecular Formula: C₉H₁₁NO
• Molecular Weight: 149.19
• Mol File: 3693-06-9.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 291.0±19.0 °C(Predicted)
• Appearance: /
• Density: 1.057±0.06 g/cm3(Predicted)
• PKA: 4.55±0.20(Predicted)
• CAS DataBase Reference: 2,3,4,5-tetrahydrobenzo[b][1,4]oxazepine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3,4,5-tetrahydrobenzo[b][1,4]oxazepine(3693-06-9)
• EPA Substance Registry System: 2,3,4,5-tetrahydrobenzo[b][1,4]oxazepine(3693-06-9)

Safety Data

• Hazardous Substances Data: 3693-06-9(Hazardous Substances Data)

Usage

General Description

2,3,4,5-tetrahydrobenzo[b][1,4]oxazepine is a chemical compound that belongs to the oxazepine family. It is a heterocyclic compound containing both nitrogen and oxygen atoms in its structure. 2,3,4,5-tetrahydrobenzo[b][1,4]oxazepine is used in the pharmaceutical industry as a building block or intermediate in the synthesis of various drugs. It has been studied for its potential pharmacological activities, including its role as an anti-inflammatory and anti-allergic agent. 2,3,4,5-tetrahydrobenzo[b][1,4]oxazepine has also been investigated for its potential use in the treatment of psychiatric disorders and neurological conditions. Overall, 2,3,4,5-tetrahydrobenzo[b][1,4]oxazepine has a wide range of potential applications in the field of pharmaceuticals and medical research.

Upstream product

• 5344-90-1 2-Aminobenzyl alcohol 
• 106-93-4 ethylene dibromide 
• 2941-78-8 2-Amino-5-methylbenzoic acid 
• 51585-35-4 7-methyl-1,2,3,5-tetrahydrobenzo[E][1,4]oxazepine 
• 4016-99-3 1-(chloroacetoxy-methyl)-2-(2-chloro-acetylamino)-benzene 
• 189940-09-8 2-chloro-N-(2-(hydroxymethyl)phenyl)acetamide 
• 3693-08-1 3,5-dihydrobenzo[e][1,4]oxazepin-2(H)-one 

Downstream Products

• 4029-39-4 1-(4-chloro-benzoyl)-1,2,3,5-tetrahydro-benzo[e][1,4]oxazepine 
• 137975-49-6 1-(4-Aminobenzoyl)-1,2,3,5-tetrahydro-4,1-benzoxazepine 
• 137975-28-1 1-(4-Nitrobenzoyl)-1,2,3,5-tetrahydro-4,1-benzoxazepine 

Relevant articles and documents

PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION

Peptidomimetic N5-methyl-N2-(nonanoyl-L-leucyl)-L-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds for use in methods of inhibiting the replication of noroviruses and coronaviruses in a biological sample or patient, for use in reducing the amount of noroviruses or coronaviruses in a biological sample or patient, and for use in treating norovirus and coronavirus in a patient, comprising administering to said biological sample or patient a safe and effective amount of a compound represented by formulae I or II, or a pharmaceutically acceptable salt thereof. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. page 99 to page 271; examples 1 to 3; compounds A1 to A104 and Bl to B66; tables A to E).

GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Substituted pyridoindoles as serotonin agonists and antagonists

The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6, R7, R8, R9, X, b, k